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The GAGE cancer testis antigen gene family encodes products that can be recognized by autologous T cells, and GAGE proteins
have been suggested as potential targets for cancer immunotherapy. Analysis of GAGE expression in tumours has primarily been
performed at the level of gene transcription, whereas little is known about GAGE expression at the protein level. To evaluate the
potential of GAGE proteins as targets for cancer-specific immunotherapy, we studied the expression of these proteins in normal and
malignant cells/tissues using a novel panel of monoclonal antibodies. Immunohistochemical analysis of more than 250 cancer
specimens demonstrated that GAGE proteins were frequently expressed in numerous cancer types and correlated with the
expression of the cancer testis antigens MAGE-A1 and NY-ESO-1. Significant intercellular and subcellular differences in GAGE
protein levels were observed, and most GAGE-positive tumours also contained cancer cells lacking GAGE expression. Studies of
genetically homogenous cell lines with similar intercellular heterogeneous GAGE expression showed that GAGE expression was not
associated with a specific genotype, but defined a phenotypically distinct population of cells. Surprisingly, in normal tissues we found
that GAGE proteins were not restricted to testis, but were also present in a subset of oocytes of resting primordial follicles and in
maturing oocytes. This is the first time that a cancer testis antigen has been reported in postfoetal oocytes. The lack of GAGE
expression in a subset of cancer cells within GAGE-positive tumours has decisive implications for the development of GAGE-targeted
cancer therapy.
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Cancer/testis (CT) antigens are proteins encoded by genes that are
normally expressed only in the human germline, but which are also
expressed in various tumour types. Restriction of CT antigen
expression to immunoprivileged normal tissues (Head and
Billingham, 1985; Hutter and Dohr, 1998) and high-frequency
expression in different types of cancer make them attractive
candidates for cancer-specific immunotherapy (Scanlan et al,
2002). A large number of CT antigens can be clustered into families
containing multiple homologous members (e.g. GAGE, MAGE,
NY-ESO-1), while others exist as nonfamily genes. Most CT
antigens are chromosome X-linked genes, and the recently
published final assembly of chromosome X indicated the existence
of more than 99 CT antigens (Ross et al, 2005).
The GAGE gene family consists of at least eight genes encoding
proteins of high identity, which can be divided into three groups
based on different features (De Backer et al, 1999). GAGE-1 is the
most unique because of an exclusive C-terminal encoded by an
exon that has been interrupted in the other GAGE genes. The
remaining GAGE members share more than 98% identity, but can
be separated into two groups, GAGE-2, -8 and GAGE-3-7, based on
the presence of a potentially phosphorylated tyrosine (Y9) in the
latter group (Salomon et al, 2003). This tyrosine is also absent in
GAGE-1. The induction mechanisms of CT antigen expression in
tumours have been investigated. Interestingly, expression of
several CT antigens, including GAGE, can be induced by the
hypomethylating agent 5-aza-20-deoxycytidine (Sigalotti et al,
2002), and it has been shown that induction of transcription
correlates with hypomethylation of CT antigen promoters (Janssen
et al, 1999; De Smet et al, 2004). There also seem to be individual
differences in the regulation of the transcription of GAGE genes
since the GAGE members are not always co-expressed (Kobayashi
et al, 2000; Eichmuller et al, 2002; Eichmuller et al, 2003).
GAGE gene transcripts have been found in numerous types
of cancers, most frequently in melanomas (De Backer et al,
1999; Eichmuller et al, 2002) and lung adenocarcinomas
(De Backer et al, 1999), in which up to 54% of specimens were
found to express GAGE, as well as in gastric cancers (Zambon et al,
2001; Kong et al, 2004) and hepatocellular carcinomas (Kobayashi
et al, 2000).
Furthermore, GAGE has been correlated with poor prognosis in
stomach cancer, esophageal carcinoma and neuroblastoma
(Cheung et al, 2000; Zambon et al, 2001; Kong et al, 2004). Received 25 January 2006; revised 30 March 2006; accepted 5 April 2006
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although antiapoptotic properties of GAGE-7 have been reported
(Cilensek et al, 2002). If confirmed, this observation may
have significant implications for cancer therapy, since
inhibition of apoptotic pathways may render cancer cells resistant
to therapy.
Evaluation of the potential of GAGE proteins as targets for
cancer-specific immunotherapy requires study of GAGE expres-
sion on the protein level. The present study describes the analysis
of GAGE protein expression in normal and cancer cells and tissues.
The expression pattern of GAGE proteins was further compared to
that of MAGE-A1 and NY-ESO-1.
MATERIALS AND METHODS
Cell cultures
The human medullary breast cancer cell line BrCa-MZ-01 was
a gift from Professor V Mo ¨bus, Universita ¨tsklinikum, Ulm,
Germany. The BrCa-MZ01-A7, -B2, -B7, -K6 and -K11 cell lines
was established from BrCa-MZ01 by three rounds of limited
dilution cloning. The malignant melanoma cell line MZ2-MEL was
a gift from Olivier De Backer, Ludwig Institute for Cancer
Research, Brussels, Belgium, while the MDA-MB-231 (HTB-26)
and the CHO-K1 cell lines were purchased from the ATCC
(Manassas, VA, USA). All cell lines were grown as monolayers in
Dulbecco’s modified Eagle’s medium (Invitrogen, Taastrup, Den-
mark), supplemented with 10% FCS, 1% nonessential amino acids,
1% L-glutamine, 1% sodium pyruvate, penicillin (100Uml
 1) and
streptomycin (100mgml
 1).
Bacterial expression and purification of GAGE-7-
glutathione S-transferase
The coding sequence of GAGE-7 was amplified from medullary
breast cancer cell line BrCa-MZ01 cDNA using primers 50-CCG
GAA TTC ATG AGT TGG CGA GGA AGA TCG-30 and 50-ATA GTT
TAG CGG CCG CTC AAC ACT GTG ATT GCT TTT CAC CTT CT-
30. The product was digested with EcoR1 and Not1 and ligated into
predigested vector pGEX-4T-1 (Amersham Pharmacia Biotech,
Piscataway, NJ, USA) for expression of glutathione S-transferase
(GST) fusion proteins. Escherichia coli BL21, carrying the GAGE-7-
pGEX-4T-1 construct, was grown in SB-media at 371C. When
OD600 was approximately 1.0, cultures were induced with 0.2mM
isopropyl-beta-D-thiogalactopyranoside for 2h at 301C. Bacteria
were pelleted, resuspended in PBS with Complete protease
inhibitor (Roche Diagnostics, Penzberg, Germany) and lysed by
sonication. GAGE-7-GST was purified with GSTrap (Amersham
Pharmacia Biotech) in accordance with the manufacturer’s
recommendations.
Production and purification of monoclonal antibodies
Balb/c mice were immunized five times at 2-week intervals with
50mg of GAGE-7-GST emulsified with TiterMax Gold adjuvant
(Stratech Scientific Ltd., Cambridgshi, Sohan, UK). At 3, 2 and 1
days before splenic recovery, 15mg of GAGE-7-GST in PBS was
injected into the dorsal tail vein of experimental mice. Hybridomas
of mouse spleen B-cells and Sp2/mIl-6 myeloma cells were
produced using the polyethylene glycol method (Kohler and
Milstein, 1975). Hybridomas producing anti-GAGE-7mAbs were
identified by direct ELISA using MaxiSorp plates (Nalge-Nunc
International, Kamstrup, Denmark) coated with GAGE-7-GST or
GST. Positive clones were re-cloned three times using serial
dilution. Hybridomas were cultivated in Dulbecco’s modified
Eagle’s medium (Invitrogen, Taastrup, Denmark), supplemented
with 10% FCS, 1% nonessential amino acids, 1% L-glutamine, 1%
sodium pyruvate, penicillin (100Uml
 1), streptomycin
(100mgml
 1) and 0.05mM 2-mercaptoethanol and mAbs were
purified using Protein G conjugated sepharose.
Mammalian expression of GAGE
GAGE-1, GAGE-2 and GAGE-7 were amplified from cDNA of MZ2-
MEL or BrCa-MZ01 cells using the primers: 50-CTG GAG CTC GCC
ACC ATG TGG CGA GGA AGA TCG ACC TAT CGG-30 (GAGE-1,-
2,-8-sense) or 50-CTG GAG CTC GCC ACC ATG TGG CGA GGA
AGA TCG ACC TAT TAT T-30 (GAGE-3-7-sense) and 50-CTT GAT
ATC ACA CTG TGA TTG CTT TTC ACC TTC TTC AGG CG-30
(GAGE-2-7-antisense) or 50-CTT GAT ATC CTC AAG GTT TCC
GTG GGG AAA GA-30 (GAGE-1-antisense). The product was
digested with EcoRV and Sac1 and ligated into predigested vector
pCMV-Tag4A (Stratagene, La Jolla, CA, USA) for expression of
proteins with C-terminal FLAG tag. pCMV-Tag4A-GAGE-1,
pCMV-Tag4A-GAGE-2, pCMV-Tag4A-GAGE-7 constructs or
pCMV-Tag4A were transfected into CHO-K1 cells using the JetPei
transfection reagent (Poly Plus Transfection, Illkirch, France) in
accordance with the manufacturer’s recommendations. At 24h
post-transfection the cells were analysed by Western blotting or
immunocytochemistry.
Quantitative RT–PCR
Relative quantification was performed in triplicate using the
standard curve method and SYBR Green PCR Master mix (Applied
Biosystems, Foster City, CA, USA) in accordance with the
recommendations of the producer. The median relative expression
levels were normalized with endogenous glyseraldehyde-3-phos-
phate dehydrogenase levels. The primers for specific amplification
were: GAPDH-sense, 50-TGC ACC ACC AAC TGC TTA GC-30,
GAPDH-antisense, 50-GGC ATG GAC TGT GGT CAT GAG-30,
GAGE-1,-2,-8-sense, 50-50-GAA GAT CGA CCT ATC GGC-30,
GAGE-3-7-sense, 50-CGA GGA AGA TCG ACC TAT TAT T-30,
GAGE-1-8-antisense, 50-GCT GGT TCC ACT TCA TCA CTG-30.
The quantifications were performed twice in their entirety, and the
similar relative fold changes confirmed the reproducibility of the
methods.
Western blotting
Sub-confluent monolayers of cells were washed twice in PBS, lysed
in 50mM HEPES (PH 7.0), 500mM NaCl, 1% NP-40 for 30min on
ice and cleared by centrifugation at 15000rpm for 10min at 41C.
Samples were resolved by 4–20% SDS–PAGE and electroblotted
onto a PVDF membrane. The membrane was incubated in PBS,
0.1% Tween-20, and 5% nonfat dry milk powder to block
remaining protein binding sites, and then incubated with anti-
GAGE mAbs M2, M3 or M4 (1/5000; produced in-house) or with
anti-GAGE-7mAb clone 26 (1/5000; BD Biosciences, Franklin
Lakes, NJ, USA) followed by horseradish peroxidase conjugated
goat anti-mouse IgG (1/100000) (DakoCytomation Denmark A/S,
Glostrup, Denmark). All antibody incubations and washing steps
were carried out in PBS, 0.1% Tween-20. The immunoreactive
bands were visualized with ECL Western Blot kit (Amersham
Biosciences, Hilleroed, Denmark).
Immunohistochemistry
Sections of tissues were cut, deparaffinized, treated with 1.5% H2O2
in Tris-buffered saline (pH 7.5) for 10min to block endogenous
peroxidase activity, rinsed in distilled H2O, demasked processed
for antigen retrieval and washed in TNT buffer (0.1 M Tris, 0.15 M
NaCl, 0.05% Tween-20, pH 7.5). A panel of antigen retrieval
protocols was initially evaluated including microwave boiling for
15min in (1) T-EG buffer (10mM Tris, 0.5mM EGTA, pH 9.0), (2)
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(Dako S1699), or proteolytic treatment using (4) 0.05% protease
type XIV (pronase E, Sigma, cat. no. P5147) in TBS, pH 7.0 for
15min at 371C or (5) 0.4% pepsin (Sigma, cat. no. P7012) in 0.01 M
HCl for 20min at 371C. The microwave boiling in T-EG buffer for
15min was found to be the optimal antigen retrieval method
for both anti-GAGE-1-8, MAGE-A1 and NY-ESO-1mAbs and was
used in the successive experiments. Sections were subsequently
incubated with anti-GAGE mAbs M2, M3 or M4 (1/100), anti-
GAGE-7mAb (1/2000; Clone 26, BD Biosciences), anti-MAGE-
1mAb (1/200; Clone MA454, Lab Vision Corporation, Newmarket
Suffolk, UK) or anti-NY-ESO-1mAb (1/25; Clone E978,
Zymed Laboratories Inc., San Francisco, CA, USA) diluted in
antibody diluent (S2022, DAKO Cytomation, Glostrup,
Denmark) for 1h at room temperature. Sections were washed
with TNT and incubated with horseradish peroxidase-conjugated
‘Ready-to-use’ EnVisiontþ polymer K4001 (DAKO Cytomation)
for 30min, followed by another wash with TNT. The final
reaction product was visualized by incubating with 3,30-diamino-
benzidine (DAB)þ substrate-chromogen for 10min, followed by
washing with H2O and counterstaining of sections with Mayers
hematoxylin before mounting in AquaTex (Merck Inc., White-
house Station, NJ, USA). For each experiment, a sample with either
an isotype-matched antibody or no primary antibody was included
as control.
Immunocytochemisty
Cells grown as monolayers were fixed in 4% formaldehyde/PBS for
15min and permeabilized in 0.25% Triton X100, PBS for 10min.
Cells were incubated with 5% normal goat serum, PBS for 30min
and with anti-GAGE mAbs M2, M3, M4 (1/400) or anti-GAGE-
7mAb clone 26 (1/400) for 90min in 1% normal goat serum, PBS.
After washing, the cells were incubated for 60min in FITC-
conjugated goat anti-mouse IgG (1/300; Jackson ImmunoResearch
Laboratories, West Grove, PA, USA), supplemented with 5mgml
 1
propidium iodide or 300nM DAPI for the last 5min. Cells were
washed again and the slides were mounted with Slow Fade in PBS/
glycerol (Molecular Probes, Eugene, OR, USA) and visualized
using fluorescence confocal microscopy or fluorescence micro-
scopy.
RESULTS
Generation and characterization of GAGE-reactive mAbs
To study GAGE expression at the protein level, a panel of mAbs
was generated by immunization of mice with purified GAGE-7-
GST fusion protein and selection based on their reactivity in ELISA
with GAGE-7-GST, but not with GST alone. From a larger panel,
three unique clones, mAbs M2, M3 and M4, as determined by
sequence analysis of heavy chains, were selected for further
characterization.
Two GAGE mRNA-positive cell lines, melanoma cell line MZ2-
MEL and breast cancer cell line BrCa-MZ01, and one GAGE
mRNA-negative cell line, breast cancer cell line MB231, were
identified by quantitative RT–PCR and analysed in Western blots
using the purified mAbs (Figure 1A and B). The three mAbs were
shown to recognize a 26-kDa band in both reduced and unreduced
lysates of MZ2-MEL and BrCa-MZ01, but did not react with a
lysate of MB231. MAbs M2, M3 and M4 were also tested for their
reactivity with recombinant proteins of each GAGE subgroup, and
were shown to recognize bands of approximately 27kDa in lysates
of GAGE-2- and -7-transfected cells, corresponding to the expected
size of recombinant GAGE-2 and -7, including the FLAG tag
(Figure 1C). Furthermore, all three antibodies recognized a band of
approximately 30kDa in GAGE-1-transfected cells, corresponding
to the expected size of GAGE-1. None of the antibodies reacted
with lysates of pCMV-Tag4A-transfected cells (negative control).
Immunocytochemical analysis confirmed that mAbs M2, M3 and
M4 reacted with members of all GAGE subgroups (data not
shown).
Analysis of GAGE protein expression in normal human
tissues
To analyse GAGE-1-8 protein expression in normal tissues, the
anti-GAGE mAbs were used for immunohistochemical staining of
24 different normal tissues (Table 1). As expected, testis was
positive for GAGE (Figure 2A), and the testicular reactivity was
localized to the seminiferous tubuli, where nuclear and cyto-
plasmic staining of both spermatogonia and primary spermato-
cytes was observed. All spermatogonia and primary spermatocytes
exhibited weak cytoplasmic staining, while strong nuclear staining
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Figure 1 Analysis of the reactivity of anti-GAGE mAbs M2, M3 and M4. (A) Both GAGE-1,-2,-8 and GAGE-3-7 were shown, by real-time PCR, to be
expressed in melanoma cell line MZ02-MEL and breast cancer cell line BrCa-MZ01, but not in the breast cancer cell line MB231. (B) M3 reacted with a 26-
kDa protein in lysates of MZ2-MEL and BrCa-MZ01, but not with a lysate of the GAGE-negative cell line MB231. The reactivity of M3 was similar to that of
M2 and M4 (not shown). (C) mAbs M2, M3 and M4 reacted with a 27-kDa band in lysates of pCMV-Tag4A-GAGE-2 and pCMV-Tag4A-GAGE-7-
transfected CHO-K1 cells, corresponding to the size of recombinant GAGE-2 or -7, including the 1-kDa FLAG tag. M2, M3 and M4 also reacted with a 30-
kDa band in lysates of pCMV-Tag4A-GAGE-1-transfected CHO-K1 cells, corresponding to the expected size of recombinant GAGE-1, including the 1-kDa
FLAG tag.
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Some heterogeneity in the staining intensity of spermatogonia was
observed. No staining of secondary spermatocytes, spermatids,
Sertoli or Leydig cells was seen.
Interestingly, cytoplasmic GAGE staining was also found in a
subset of oocytes (about 30%) of primordial resting follicles in
ovary specimens (Figure 2D). No morphological differences
between GAGE-positive and GAGE-negative oocytes were detected.
A maturing follicle was also identified and the oocyte residing in
the cumulus ooforus was intensely stained for GAGE (Figure 2E).
No GAGE expression was detected in the other normal tissues
examined, as outlined in Table 1, and no apparent differences in
the reactivity of mAbs M2, M3 and M4 were observed.
For comparison, the 24 normal tissues were also examined for
MAGE-A1 and NY-ESO-1 expression using the mAbs MA454 and
E978, respectively (Jungbluth et al, 2000; Vaughan et al, 2004)
(Table 1). Both mAbs reacted with the cytoplasm of spermatogonia
and primary spermatocytes, but MAGE-A1 staining was strong in
spermatocytes and weaker in spermatogonia, whereas the opposite
was observed for NY-ESO-1 (Figure 2B and C). No staining of
secondary spermatocytes, spermatids, Sertoli or Leydig cells was
seen. In contrast to the anti-GAGE mAbs, neither of the MAGE-A1
the NY-ESO-1 mAbs reacted with the nucleus of spermatogonia
and primary spermatocytes, nor did they react with oocytes of the
ovary. The staining patterns of MAGE-A1 and NY-ESO-1
antibodies was in accordance with previous studies (Jungbluth
et al, 2000; Jungbluth et al, 2001).
Analysis of GAGE protein expression in tumours
The GAGE-1-8 specific mAbs were also tested for reactivity with
more than 250 cancer specimens, as summarized in Table 2.
Among breast carcinomas, lung carcinomas and malignant
melanomas, which represented the largest groups in the tumour
panel, the incidences of GAGE expression were 12% (5/43),
16% (10/64), and 17% (4/24), respectively (Figure 2F–L).
GAGE expression could not be correlated with any specific
subtype of these cancers. GAGE-positive specimens were also
identified within the smaller panels of bladder carcinomas, liver
carcinomas, mesotheliomas, thyroid carcinomas and germinal cell
tumours.
The staining pattern within a given tumour varied significantly
both in the frequency of tumour cells exhibiting GAGE expression,
in the intensity of staining and in the subcellular localization of the
staining (Figure 2F–L). For example, in malignant melanomas,
most cancer cells were GAGE-positive, while in other cancer types
only few cells expressed GAGE. Furthermore, all GAGE-positive
melanoma cells exhibited cytoplasmic staining, but there were
clear differences in the nuclear staining. Some melanomas showed
intense staining of all nuclei (Figure 2G), while other specimens
contained only about 50% of positive nuclei (Figure 2H) or no
nuclear staining (Figure 2I). In one breast carcinoma (Figure 2L)
and one seminoma, very few cells were positive, and these cells
were situated in the tumour in a nonclonogenic manner. In
another breast carcinoma, focal parts of the tumour were positive
(Figure 2J and K). Importantly, cancer cells that did not exhibit
GAGE staining were observed in most GAGE-positive tumours.
For comparison, the same panel of 256 tumour specimens was
tested for MAGE-A1 and NY-ESO-1 protein expression. MAGE-A1
was detected in the same types of cancer as GAGE, but also in
specimens of endometrial carcinoma and pheochromocytoma.
Within the large groups of the tumour panel, the highest
incidences of MAGE-A1 expression were observed in bladder
carcinoma (40%), lung carcinoma (32%), malignant melanoma
(21%) and breast carcinoma (11%). NY-ESO-1 expression, as
determined by mAb E978 staining, was restricted to a smaller
number of cancer types than GAGE and MAGE-A1. Staining was
observed in specimens of malignant melanoma, lung carcinoma,
lymphoma and germinal cell tumours. Similar to GAGE, NY-ESO-1
was present in both the cytoplasm and nucleus of cancer cells. In
contrast, MAGE expression was strictly cytoplasmic in both germ
cells and cancer cells (data not shown).
In total, 62/256 (24%) of the tumour specimens included in this
analysis were positive for at least one of three CT antigens. In all,
32 (13%) stained for GAGE, 43 (17%) stained for MAGE-A1 and 18
(7%) stained for NY-ESO-1 (Figure 3). Of the 62 CT antigen-
positive tumours, 22 (35%) were positive for two CT antigens
(most often GAGE and MAGE-A1) and five (8%) were positive for
all three CT antigens, suggesting a significant correlation of the
expression of these CT antigens. The highest incidence of co-
expression was observed in malignant melanoma, where 3/12 CT
antigen-positives specimens were stained for both GAGE, MAGE-
A1 and NY-ESO-1. Interestingly, within tumours that co-expressed
CT antigens, cells that expressed one CT antigen but not another
were identified.
Immunofluorescent microscopy analysis of the subcellular
localization of GAGE proteins
The subcellular distribution of GAGE proteins was further
examined in cells of the melanoma cell line MZ2-MEL and the
breast cancer cell line BrCa-MZ01-A7 by confocal microscopy
(Figure 4A–L). GAGE proteins were evenly distributed in the
cytoplasm of all MZ2-MEL cells, while staining of the nuclei was
either intense (Figure 4E–H) or completely absent (Figure 4A–D).
In BrCa-MZ01-A7, only about 5% of the cells were stained. As in
the MZ2-MEL cells, all the GAGE-positive BrCa-MZ01-A7 cells
exhibited cytoplasmic staining, while the nuclei were either
intensively stained or negative (Figure 4I–L). In a small number
of cells of both cell types, GAGE staining was confined to the
nuclear envelope (data not shown). Nucleoli appeared to be
negative in all GAGE-positive nuclei.
The subcellular localization of the individual GAGE members
was addressed by immunofluorescent microscopy analysis of
GAGE-1-, -2- or -7-transfected CHO-K1 cells (Figure 4M–P). The
staining patterns of all three GAGE proteins were similar to those
Table 1 Immunoreactivity of mAbs directed against GAGE, MAGE-1 or
NY-ESO-1 with normal tissues (+ positive;   negative)
Tissue GAGE (M3) MAGE-A1 (MA454) NY-ESO-1 (E978)
Bladder     
Cerebellum     
Cerebrum     
Gallbladder     
Kidney     
Liver     
Lung     
Muscle     
Oesophagus     
Ovary +   
Pancreas     
Parathyroid gland     
Parotis     
Placenta     
Prostate     
Rectum     
Skin     
Small intestine     
Spleen     
Testis + + +
Thymus     
Thyroid gland     
Tonsil     
Ventricle     
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sof MZ2-MEL and BrCa-MZ01-A7. Transfected cells exhibited
cytoplasmic staining and varying nuclear staining, while a
minority of cells showed strong staining of the nuclear envelope
(Figure 4M and N). No apparent differences in the subcellular
localization of GAGE-1, -2 or -7 were observed.
Heterogeneity of GAGE expression in BrCa-MZ01
subclones
To determine whether variations in GAGE expression
were associated with genetic variability, five cell lines, that is
Figure 2 Comparison of GAGE, MAGE-1 and NY-ESO-1 staining in normal testis, and analysis of GAGE protein expression in ovary and different types
of cancer. GAGE (A), MAGE (B) and NY-ESO-1 (C) were detected in spermatogonia and primary spermatocytes of the seminiferous tubuli. However,
while MAGE-A1 and NY-ESO-1 were located only in the cytoplasm of these cells, GAGE staining was also present, and more intense, in the nuclei. GAGE
was also expressed in oocytes of resting (D) and maturing (E) follicles of normal ovaries, which also contained GAGE-negative oocytes. In three malignant
melanomas, all cells exhibited cytoplasmic staining (G–I), whereas nuclear staining was observed in only two melanomas (G and H). Heterogeneous
staining was also seen in other types of cancer, including lung carcinoma (F) and breast carcinoma (J–L). One breast carcinoma exhibited variations in both
cytoplasmic and nuclear GAGE staining among cells (J and K), while only few cells of another breast cancer specimen were positive (L). Magnification:  10
(A, B, C, E, F, J, L),  20 (G–I),  40 (D, K).
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single cells of the original BrCa-MZ01 cell line by three rounds of
limited dilution cloning and GAGE expression was assessed.
Quantitative PCR showed that cell lines BrCa-MZ01-A7, -B2, -K6
and -K11 expressed GAGE-1,-2,-8 and GAGE-3-7 mRNA, while
BrCa-MZ01-B7 was negative for both (Figure 5A). Immunocyto-
chemical analysis further showed that only 5–30% of BrCa-MZ01-
A7, -B2, -K6 and -K11 cells were GAGE-positive, and that the
positive cells were clonally derived (Figure 5B), suggesting that
GAGE expression is not associated with a specific genotype, but
with a phenotypically distinct population of cells.
Comparison of the reactivity of the anti-GAGE mAbs with
that of a commercial anti-GAGE-7 antibody
During the latter part of this study, a commercial anti-GAGE-
7mAb (clone 26; BD Biosciences) became available. This antibody,
which recognized a 26-kDa band, similar to our anti-GAGE mAbs,
was recommended only for Western blot applications by the
manufacturer, but two recent studies have shown that this
mAb is also suitable for immunohistochemical analysis
(Luftl et al, 2004; Akcakanat et al, 2006). To compare the reactivity
of this antibody with the reactivity of mAbs M2, M3 and M4,
the anti-GAGE-7mAb was tested in parallel with M3 for reactivity
with the panel of normal and cancer tissues by immuno-
histochemistry. The reactivity pattern for the two antibodies was
identical within both normal tissues, including reactivity with
spermatogonia, primary spermatocytes and oocytes, and within
the cancer tissues.
DISCUSSION
CT antigens are currently a major focus of cancer research due to
their potential as targets for cancer-specific immunotherapy. For
this purpose, it is essential to determine the types of cancer that
express CT antigens, at what frequency, and the pattern of
expression within a given tumour, including percentage of positive
cells, expression levels and the subcellular localization of expres-
sion. The expression of GAGE proteins in tumours has been
addressed by RT–PCR in numerous studies, but until recently no
anti-GAGE antibodies were available (Luftl et al, 2004; Akcakanat
et al, 2006). In this study, we have generated a panel of GAGE-
reactive mAbs and used these to characterize the extent of
heterogeneity in GAGE expression in malignancies.
Using our mAbs, GAGE protein expression was identified in
specimens of malignant melanoma, breast carcinoma, bladder
carcinoma, lung carcinoma, liver carcinoma, thyroid carcinoma,
mesothelioma and germinal cell cancers. Importantly, our study
demonstrated significant variations in the level of GAGE expres-
sion in the different tumours, and within the majority of the
tumours analysed we also observed an intercellular heterogeneity
of GAGE protein expression that included GAGE-negative cells.
This may have important implications for the development of
GAGE-targeted cancer vaccines, since GAGE-negative cells within
GAGE-positive tumours may escape treatment.
The degree of co-expression of GAGE, MAGE-A1 and NY-ESO-1
genes in tumours was evaluated by immunohistochemical analysis
of parallel tissue sections and a significant correlation between the
expression of these CT antigens, GAGE and MAGE-A1, in
particular, was found among cancer types and specimens.
Interestingly, the proteins were not consistently co-expressed
and within a tumour that expressed more than one CT antigen
subpopulations of cancer cells were observed that were positive for
one CT antigen and negative for another.
The frequencies of GAGE-positive tumours within the different
cancer types assessed in our immunohistochemical analyses were
somewhat lower than the frequencies of previous mRNA-based
studies on the same types of cancer. For example, GAGE
expression in malignant melanomas was observed in 17% of
specimens in our study, while a previous study showed that 30% of
malignant melanomas were GAGE-1-8 mRNA-positive (Eichmuller
et al, 2002). Similar differences were observed for lung carcinoma
(16 vs 50%), thyroid carcinoma (10 vs 30%) and ovarian carcinoma
(0 vs 30%) (Russo et al, 1996; De Backer et al, 1999; Ruschenburg
et al, 1999; Kobayashi et al, 2000). Lower frequencies of tumours
exhibiting MAGE-A1 and NY-ESO-1 staining, compared to
previous mRNA-based studies, were also observed (Li et al,
1996; Zambon et al, 2001; Kong et al, 2004; Wang et al, 2004; Li
et al, 2005). In accordance with our results, a lower frequency of
immunohistochemical-positive tumours compared to mRNA-
positive tumours was recently reported in a study addressing
GAGE, MAGE-A1 and NY-ESO-1 expression in oesophageal
carcinomas (Akcakanat et al, 2005). These discrepancies are most
likely the result of differences in the amount of tumour tissue
Table 2 Immunoreactivity of mAbs directed against GAGE, MAGE-1 or
NY-ESO-1 with cancerous tissues (npositive/ntotal)
Tumour type GAGE (M3)
MAGE-A1
(MA454)
NY-ESO-1
(E978)
Appendix carcinoma 0/2 0/2 0/2
Bladder carcinoma 4/10 4/10 0/10
Breast carcinoma 5/43 5/43 0/43
Cervix carcinoma 0/6 0/6 0/6
Colorectal carcinoma 0/9 0/9 0/9
Endometrial carcinoma 0/15 1/15 0/15
Gastric carcinoma 0/9 0/9 0/9
Germinal cell tumours total 5/10 3/10 3/10
Dysgerminoma embryonal 1/1 0/1 0/1
Carcinoma 1/4 1/4 1/4
Granulosa cell tumour 0/1 0/1 0/1
Seminoma 2/3 2/3 2/3
Teratoma 1/1 0/1 0/1
Kidney carcinoma 0/12 0/12 0/12
Liver carcinoma 1/2 0/2 0/2
Lymphoma 0/2 0/2 1/2
Lung carcinomas total 10/64 21/64 9/64
Adenocarcinoma 2/18 5/18 7/18
Large cell carcinoma 4/9 4/9 1/9
Small cell carcinoma 0/2 0/2 1/2
Planocellular carcinoma 2/35 12/35 0/35
Malignant fibrous histocytoma 0/1 0/1 0/1
Malignant melanoma 4/24 5/24 5/24
Mesothelioma 2/7 1/7 0/7
Ovary carcinoma 0/10 0/10 0/10
Parotis carcinoma 0/2 0/2 0/2
Pheochromocytoma 0/1 1/1 0/1
Prostate carcinoma 0/10 0/10 0/10
Rectum carcinoma 0/2 0/2 0/2
Small intestine carcinoma 0/5 0/5 0/5
Thyroid carcinoma 1/10 2/10 0/10
MAGE-A1
GAGE
NY-ESO-1
20
14
10 5 4
6 3
Figure 3 Co-expression of CT antigens in cancers. The numbers
indicate tumours that exhibited GAGE, MAGE-A1 and/or NY-ESO-1
staining among the 256 tumours tested. A significant correlation between
the expression of GAGE, MAGE-A1 and NY-ESO-1 was observed.
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analysis, a 5mm cubic tumour block is generally used. In contrast,
only a 10mm section, about 500 times less tissue, is used for
immunohistochemistry. As some tumours contain very few CT
antigen-positive cells or exhibit CT antigen expression only in
focal parts of the tumour, it is more likely that the higher number
of cells used in RT–PCR analysis vs array-based immunohisto-
chemical analysis will include CT antigen-positive cells. Support-
ing this, some tumours, which were initially identified as GAGE-
negative by immunohistochemistry, were found to contain some
GAGE-positive cells, when re-examined using sections obtained
from deeper parts of the same tumour blocks. Another, less likely,
explanation may be that the sensitivity of immunohistochemical
analysis is lower than that of RT–PCR analysis.
GAGE/FITC
GAGE-1/FITC GAGE-2/FITC GAGE-2/FITC GAGE-7/FITC
DNA/PI Combined DIC
A
E
I
MN OP
JKL
FGH
BCD
Figure 4 Subcellular localization of GAGE proteins in cancer cell lines. MAb M4 reacted with GAGE in melanoma MZ2-MEL cells (A–H), exhibiting weak
cytoplasmic staining of all cells and strong (E–H)o rn o( A–D) staining of nuclei. A similar staining pattern was observed for breast cancer cell line BrCa-
MZ01-A7 (I–L), but only about 5% of the cells were positively stained. MAb M4 also reacted with recombinant GAGE expressed in CHO-K1 cells (M–P).
The staining patterns of cells transfected with GAGE-1, -2 or -7 constructs were similar to those of MZ2-MEL and BrCa-MZ01-A7 cells. Transfected cells
exhibited cytoplasmic staining and strong or no nuclear staining, and some cells had a distinct staining of the nuclear envelope (M and N), which was also
observed in some MZ2-MEL and BrCa-MZ01-A7. Staining was visualized by immunofluorescent confocal microscopy (A–L) or immunofluorescent
microscopy (M–P). Magnification:  100.
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demonstrated that all positive cells exhibited weak cytoplasmic
staining and variable nuclear staining in both cancer and normal
cells (e.g. germ cells). This suggests that CT antigens are expressed
in a natural context when expressed in cancer cells, and thus may
play a functional role in these cells. It also supports the hypothesis
that CT antigens are expressed as a part of a coordinated
gametogenic program that can be activated in cancer cells and
that could account for the many similarities between germ cells
and cancer cells (Scanlan et al, 2002).
To investigate the mechanisms that control the GAGE expres-
sion, we also addressed GAGE expression in cancer cell lines. A set
of genetically-homogenous subclones were established from the
BrCa-MZ01 cell line by three rounds of subcloning. Interestingly,
we found that only 5–30% of the cells of these subclones expressed
GAGE, suggesting that GAGE expression is not associated with a
specific genotype, but is linked to a specific phenotype. It has
recently become evident that some tumours consist of a
heterogeneous population of cells with a hierarchical organization,
and that the capability of sustained tumour growth resides
exclusively within a small proportion of cells that posses stem
cell-like characteristics (Al-Hajj et al, 2003; Bapat et al, 2005; Ponti
et al, 2005). Furthermore, it has been shown that a similar
organization exists in some cancer cell lines (Kondo et al, 2004;
Setoguchi et al, 2004; Ponti et al, 2005). The clonogenic nature of
GAGE expression in cells of the genetically homogenous BrCa-
MZ01 subclones suggests that expression of GAGE proteins is
associated with a hierarchical distinct cell population. As we and
others have shown that GAGE proteins are expressed in different
types of stem cells (e.g. spermatogonia, oocytes, human mesench-
ymal stem cells (Cronwright et al, 2005) and haematopoietic stem
cells (Guinn et al, 2005)), GAGE expression may define a
population within the BrCa-MZ01 cell line that has the character-
istics of cancer stem cells. A link between GAGE and self-renewal is
further supported by the high frequency of GAGE-positive
subclones (4/5) derived from the original BrCa-MZ01 cell line,
which had only about 5% of GAGE-positive cells. Further studies
will determine if GAGE proteins are markers of cancer stem cells
and if the heterogeneous expression of GAGE proteins in tumours
is a consequence of GAGE expression being turned off as the cells
develop towards a more committed phenotype.
Using our mAbs, we also assessed the GAGE expression in
normal tissues. As expected, high reactivity was seen in the
germ cells of the testicular seminiferous tubuli, where
spermatogonia and primary spermatocytes exhibited expression
of GAGE, while the secondary spermatocytes were unstained.
This suggests that GAGE expression is downregulated when
primary spermatocytes undergo meiosis and become secondary
spermatocytes. Interestingly, we also observed variations in the
intensity of GAGE nuclear staining among spermatogonia. Several
subtypes of spermatogonia representing different stages in early
spermatogenesis have been identified (de Rooij, 1998), and
differences in the intensity of GAGE nuclear staining may be
associated with different spermatogonial subtypes. MAGE-A1 and
NY-ESO-1 were also highly expressed in spermatogonia. However,
we found that MAGE-A1 expression was strictly cytoplasmic, in
contrast to reports by others that MAGE-A1 is also expressed
in the nucleus of spermatogonia (Takahashi et al, 1995).
In fact, MAGE-A1 was found to interact with the nuclear
proteins SKIP and HDAC1 and thereby inhibit transcriptional
activation mediated by Notch-IC (Laduron et al, 2004).
The nuclear localization of GAGE proteins in spermatogonia
suggests that GAGE may also be a regulator of germline gene
expression.
GAGE proteins were also detected in oocytes of both resting and
maturing follicles of the ovary, which is surprising since no other
CT antigen has been identified in postfoetal oocytes, but also
logical, since both oocytes and spermatogonia are derived from the
foetal primordial germ cells. Only about 30% of oocytes of
primordial resting follicles were positive and, based on the
morphology, it was not possible to differentiate between the
oocytes that exhibited GAGE staining and those that did not. The
nature of this difference in GAGE expression is currently being
investigated. Although present in foetal oogonia (Simpson et al,
2005), MAGE-A1 and NY-ESO-1 were not detected in oocytes.
Thus, regulation of GAGE, MAGE-A1 and NY-ESO-1 gene
expression in normal cells seems to depend on different
mechanisms. Our observation that GAGE proteins are expressed
in oocytes may not limit its use as a target for cancer-specific
immunotherapy, since oocytes, similar to testicular germ cells, are
recognized as immunoprivileged cells (Fenichel et al, 1995; Hutter
and Dohr, 1998).
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Figure 5 Clonal GAGE expression in BrCa-MZ01 breast cancer cells. (A) Subclones of the BrCa-MZ01 cell line were isolated as tested for GAGE
expression by real-time PCR. A7, B2, K5 and K11 were all positive for both GAGE-1,-2,-8 and GAGE-3-7, while B7 was completely negative. (B) BrCa-
MZ01-K11 cells were seeded at low density, allowed to grow for 6 days, and then stained for GAGE (FITC, green, top and bottom panel) and DNA (DAPI,
blue, middle and bottom panel). GAGE was clonally expressed in approximately 30% of the genetically-homogeneous BrCa-MZ01-K11 cells, indicating that
GAGE expression is independent of genotype. Magnification:  20.
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